In BC patients, increased CCL2 serum levels were correlated with advanced tumor stage (p = 0.04) and lymph node involvement (p = 0.04), but serum CCL2 levels could not be established as a differentiation marker between malignant and benign breast tumors [193]. This evidence concerns the gene CCL2 and breast cancer.